Tagged with CUHK

Hong Kong With Hong Kong now host to a growing volume of public and private entities specializing in cell and gene therapy development, some market insiders spy great opportunities for the city, with its unique background context and characteristics, to play a role shaping the next wave of biomedicine discovery.   Dr…

Hong Kong In summer 2023, Hong Kong entered the next frontier of cancer care with the launch of its first hospital-based CAR-T clinical trial. Developed entirely within city limits by a team of clinicians and scientists at the Chinese University of Hong Kong (CUHK), Prince of Wales Hospital, and the Hong Kong…

Hong Kong In March 2024, the Advanced Therapy Product Good Manufacturing Practice Centre (ATP GMP Centre) at the Chinese University of Hong Kong’s (CUHK) Institute of Biotechnology (HKIB) became the first university-led centre within the special administrative region to receive certification for cell and gene therapy manufacturing and a license as an…

Global Throughout the year PharmaBoardroom has talked to pharma and biotech executives and life sciences opinion leaders across the globe, gathering vital insights into local markets, learning about promising new therapies, and examining the broader trends shaping the industry. Here is a selection of some of the year’s most-read interviews.  …

China Diabetes is a growing health concern in China and – given the country’s population size – a major contributor to global diabetes levels. Indeed, a recent study in The Lancet estimates that China accounts for almost 18 percent (148 million) of the world’s 828 million diabetics, while World Bank data…

Hong Kong Professor at the Chinese University of Hong Kong since 1993 and pioneer in studying the causes of stroke in China, Lawrence Wong comments on neurology advancements over the past 30 years; the increasing number of Alzheimer’s cases amongst Asian populations, and the need to go from a symptomatic approach to…

Hong Kong Prominent oncologist and chair of the clinical oncology department at the Chinese University of Hong Kong Professor Tony Mok comments on the potential  of the Antibody Drug Conjugates (ADC) platform and discusses boosting clinical trials in Hong Kong and the difficulties posed by a shortage of doctors in the territory.…

Hong Kong Dr Jeremy Teoh highlights the importance of Hong Kong’s role in global urology research, emphasizing collaborations with international institutions and the Greater Bay Area. Despite the challenges of Hong Kong’s smaller scale, its strategic position allows it to bridge Eastern and Western medical practices, elevating research standards globally. Dr Teoh…

Hong Kong Professor Justin Che-Yuen WU outlines how strategic collaborations in the Greater Bay Area are expanding CUHK’s influence in medical innovation, healthcare services, and clinical research. Professor Wu explains how these collaborations are crucial for integrating Hong Kong’s advanced medical practices into mainland China while leveraging the region’s resources for innovation…

Hong Kong A surgeon by training, Prof Philip Chiu is now dean of the Faculty of Medicine at the research-focused Chinese University of Hong Kong (CUHK). He shares the creation of CUHK’s Multiscale Medical Robotics Centre and the robotic system for minimally invasive surgery developed there; CUHK’s focus on translational medicine and…

Hong Kong Insighta, formed this year as a 50/50 joint venture between genomics-focused outfit Prenetics and one of the city’s most feted scientific sons, Professor Dennis Lo, is aiming to change the face of cancer care via widespread early detection.   While early detection is widely recognised as crucial to enhancing cancer…

Hong Kong One of Asia’s most pre-eminent oncologists, Professor Tony Mok is perhaps best known for discovering the EGFR mutation gene and subsequently developing a targeted therapy that is more precise and personalized than standard chemotherapy. Here, Professor Mok discusses his current research areas of focus, some of the key clinical trial…